Company profile

Anaveon AG

We are developing IL-2 complexes which selectively promote effector T cell functions. Our compounds act as effective immune adjuvants with a broad therapeutic window and marked preclinical efficacy against cancer either as monotherapy or in combination with other therapies.

Anaveon AG

Source: startup.ch

Highlights

Top 100 Swiss Startup Award 2022Top 100 Swiss Startup Award 2022 Top 100 Swiss Startup Award 2020Top 100 Swiss Startup Award 2020 Top 100 Swiss Startup Award 2019Top 100 Swiss Startup Award 2019

More news about Anaveon AG

19.09.2022 17:08

Encouraging results for Anaveon’s lead molecule
  • Success
    Please login or
    register to use the
    awards follow feature
    16.12.2021 08:51

    Anaveon raises CHF 110 million
  • Financing
    Please login or
    register to use the
    awards follow feature
    06.07.2021 08:32

    First patients dosed with Anaveon's lead program
  • Launch
    Please login or
    register to use the
    awards follow feature
    01.04.2019 16:45

    Swiss Biotech Day to shed light on 13 emerging startups

  • Background
  • Support
    Please login or
    register to use the
    awards follow feature
    27.02.2019 10:36

    UZH spinoff secures CHF 35 million Series A financing
  • Financing
    Please login or
    register to use the
    awards follow feature
    22.01.2019 17:01

    BaseLaunch funds four healthcare start-ups
  • Financing
  • Support
    Please login or
    register to use the
    awards follow feature
    15.06.2018 10:00

    Anaveon off to a good start with UZH Life Sciences Fund
  • Financing
    Please login or
    register to use the
    awards follow feature
    31.01.2018 10:15

    BaseLaunch selektiert sechs Startups für zweite Förderphase
  • Financing
  • Support
    Please login or
    register to use the
    awards follow feature
    Anaveon AG

    Founded
    2017

    Kanton
    BS


    LinkedIn

    Homepage

    rss